



The Open Cardiovascular Medicine Journal

Content list available at: www.benthamopen.com/TOCMJ/

DOI: 10.2174/1874192401610010001



Testosterone and Cardiovascular Disease

Amos Tambo^{1*}, Mohsin H.K. Roshan¹ and Nikolai P. Pace²

¹ Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta- Msida, Malta

² Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Biomedical Sciences Building, Msida, Malta

Abstract: Cardiovascular disease [CVD] is a leading cause of mortality accounting for a global incidence of over 31%. Atherosclerosis is the primary pathophysiology underpinning most types of CVD. Historically, modifiable and non-modifiable risk factors were suggested to precipitate CVD. Recently, epidemiological studies have identified emerging risk factors including hypotestosteronaemia, which have been associated with CVD. Previously considered in the realms of reproductive biology, testosterone is now believed to play a critical role in the cardiovascular system in health and disease. The actions of testosterone as they relate to the cardiac vasculature and its implication in cardiovascular pathology is reviewed.

Keywords: Atherosclerosis, Cardiovascular disease, Hypogonadism, Testosterone, Vascular biology.

1. INTRODUCTION

Cardiovascular disease [CVD] is the leading cause of mortality globally. It was responsible for an estimated 17.5 million deaths in 2012, which accounted for 31% of the global crude death rate [1].

CVDs primarily affect the cardiac parenchyma or vasculature [2]. They are precipitated by non-modifiable as well as modifiable risk factors. Emerging risk factors, such as hypotestosteronaemia have recently been suggested to contribute to the pathogenesis [3, 4].

The majority of CVD aetiologies can be attributed to atherosclerosis. Atherosclerosis, a specific type of arteriosclerosis, which is characterised by lipid accumulation and mononuclear leukocyte infiltration in the tunica intima of vessels, results in mural thickening [5]. Although the exact mechanisms are not fully understood, in most cases oxidised LDL [oxLDL] is often considered the culprit since it is believed to trigger a chronic inflammatory response [6, 7]. The corollary is monocyte and T-cell recruitment to the 'site of injury', where monocytes are subsequently transformed into lipid-laden macrophages foam cells along with smooth muscle cells [SMCs] and fibroblasts [8].

Eventually, atheromatous plaque formation occurs and later develops a necrotic core and fibrous cap [8]. Luminal stenosis consequently limits perfusion. Complications of atheroma include plaque rupture and resultant thromboembolism, plaque fissure, and plaque ulceration [9, 10]. Acute coronary syndromes [ACS] namely ischaemic stroke, unstable angina and myocardial infarction are also sequelae [9, 11, 12].

In 2009 the total cost of CVD per capita from all European Union member states was €212, 9% of the total healthcare expenditure [13]. CVD is therefore a pressing public health issue.

* Address correspondence to this author at the Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta- Msida, Malta; Tel: (+356) 99179052; E-mail: amos.tambo.13@um.edu.mt

2. TESTOSTERONE AND THE CARDIOVASCULAR SYSTEM

2.1. Testosterone Physiology

Testosterone is an androgen steroid hormone derived from cholesterol [14]. It circulates in two major forms: dehydroepiandrosterone sulphate [DHEA-S] and androstenedione [AS] [15]. Synthesis of testosterone and 5 α -dihydrotestosterone [5 α -DHT] occurs primarily in the Leydig cells in the testis [15]. Peripheral sites of synthesis include the zona reticularis of the adrenal cortex [DHEA-S and AS] in both sexes, and skin [testosterone and 5 α -DHT] to a lesser extent [15, 16]. Testosterone production also occurs in females from Graafian follicle theca interna cells in the form of AS, the majority of which is converted to 17 β -estradiol by the enzyme aromatase [17, 18]. Peripheral testosterone production is regulated by hypothalamic gonadotrophin-releasing hormone [GnRH] and the anterior pituitary hormone adrenocorticotropin hormone [ACTH] [16, 19]. On the other hand, gonadal synthesis is governed by GnRH and luteinising hormone [LH] [19, 20]. In both instances, feedback loops exist to ensure adequate regulation of the hypothalamic-pituitary-gonadal [HPG] axis as well as the hypothalamic-pituitary-adrenal [HPA] axis [21, 22].

2.2. Classical Functions

Testosterone acts *via* the androgen receptor [AR] to mediate an extensive array of physiological processes [23]. Primarily, testosterone is a sex hormone that determines and regulates the development of male secondary sexual characteristics [24]. It increases libido and improves erectile function, but also has a number of anabolic roles. Testosterone stimulates nitrogen retention by increasing the rate of protein synthesis and decreasing the rate of protein catabolism. It is therefore responsible for increasing muscle mass [25]. In addition, testosterone indirectly inhibits bone resorption through its conversion to estradiol [26]. DHT directly stimulates osteoblastic activity and bone growth [27]. In addition to these classical functions, testosterone is also responsible for mediating other crucial physiological processes.

2.3. Non Classical Functions

Testosterone is seldom affiliated with the circulatory system, if at all. Its role as a promoter of erythropoiesis has not extensively been discussed [28]. In fact, an elevated haematocrit is a side effect associated with administration of acute supraphysiological concentrations of testosterone [29]. Furthermore, testosterone has been implicated in cerebral physiology, though this is not without controversy. Testosterone has been shown to improve cerebral perfusion and thus mood in hypogonadal men [30, 31]. Some investigators even go as far as stating that testosterone plays significant roles in memory, strategic planning, higher order motor actions, as well as cognitive and emotional behaviours [24].

2.4. Testosterone and Cardiac Vasculature

2.4.1. Epidemiology

Hypogonadism, as defined by The Endocrine Society's Clinical Practice Guideline for Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes, is "a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone [androgen deficiency] and a normal number of spermatozoa caused by a disruption of one or more levels of the hypothalamic-pituitary-gonadal [HPG] axis" [32]. The normal testosterone laboratory reference range is 10.4 – 34.7 nmol/L [300 – 1000 ng/dL] [33]. Epidemiological studies have associated low testosterone levels with all-cause mortality and an increased risk of CVD, both of which were statistically significant [4, 34 - 36]. The association with increased risk of CVD persists even when corrected for age, as testosterone levels are known to increase at approximately age 30, and thereafter decrease with an increase in age [37 - 39]. In fact, a case control study conducted over a 7 year period, consisting of 2314 men aged 40-79 years, found that every 173 ng/dL [6 nmol/L] increase in serum testosterone was associated with a 21% lower risk of all-cause mortality after correcting for age, body mass index, systolic blood pressure, cholesterol, cigarette smoking, diabetes, alcohol intake, physical activity, social class, education, and sex hormone-binding globulin [35].

While some investigators have linked hypogonadism to an increased risk of coronary artery disease [CAD] others have failed to replicate this association [4, 40]. This discrepancy could be due to differences in study design. Some investigators failed to account for the subfraction of testosterone utilised and the serum quantification method [4]. Testosterone circulates in blood as bioavailable and bound testosterone, and both these subfractions constitute total testosterone [4]. Bioavailable testosterone makes up approximately 33% of circulating testosterone, 30% of which circulates bound to albumin and 1-3% free in blood [4]. On the other hand, the bound testosterone fraction circulates in

blood bound to Sex Hormone Binding Globulin [SHBG] and is responsible for 68% of circulating testosterone [4].

Testosterone Replacement Therapy [TRT] serves to substantiate the importance of testosterone in the cardiac vasculature in health and disease (Fig. 1). Three randomised placebo-controlled trials have shown myocardial ischaemia improvement in men with CAD, due to an extension of time to exercise-induced ST-segment depression, as measured on treadmill exercise stress test [41 - 43]. Moreover, to the best of our knowledge, there is currently no published study in the literature demonstrating a statistically significant association between TRT and cardiovascular adverse events in a large cohort.




Fig. (1). Summary diagram of the key roles of testosterone in cardiovascular system.

Most of the negative connotations attributed to the effects of androgens on the cardiovascular system stem from the observational link established between sudden death and androgen abuse in athletes [24, 38]. To the best of our knowledge, there is no study in the scientific literature presenting statistically significant data to support a causative role for anabolic androgens in cardiovascular adverse events in athletes. In this context, perhaps the chronic administration of anabolic androgens at supraphysiological rather than physiological levels leads to toxicity and death, though robust studies are needed to substantiate this.

2.4.2. Vasodilation

Testosterone is essential for normal healthy vascular function [4]. The consensus from animal studies points to its role in vasodilation [38, 44]. Deenadayalu *et al.* conducted a study in pre-contracted swine left anterior descending coronary arteries [LAD] where prostaglandin served as the contractile agent. The effects of endothelial denudation and either Krebs-Henseleit Bicarbonate [KHB] solution, or N-nitro-L-arginine methyl ester [L-NAME] on testosterone-treated vessels were tested. KHB is a well-known physiological buffer whereas L-NAME antagonises the enzyme responsible for nitric oxide production, nitric oxide synthase [NOS]. An increase in vascular relaxation percentage and vasodilatation was observed following testosterone administration in a dose-dependent fashion. This effect was not blunted by vascular denudation nor administration of L-NAME and KHB [44, 45].

There is ample evidence in the scientific literature on the vasodilatory effects of testosterone on the vascular system, though little is known about the mechanisms through which testosterone exerts this effect. It has been suggested that testosterone may trigger vasodilatation *via* endothelial-independent non-genomic means, given its rapid onset, though potentiation by genomic means *via* the classical AR cannot be excluded [38, 44, 46]. Inhibition of voltage-operated calcium channels [VOCCs] and/or activation of potassium channels [KCs] on smooth muscle cells [SMCs] is believed to be instrumental. Testosterone binds the same domain as nifedipine on VOCCs and thus promotes vasodilation by

inactivating VOCCs. An alternate postulate is the activation of voltage-operated potassium channels by testosterone and/or activation of calcium-activated potassium channels which give rise to hyperpolarisation, due to potassium efflux. It has also been suggested that testosterone can inhibit calcium influx through store-operated calcium channels [SOCCs] by blunting the response to prostaglandin F_{2α} [PGF_{2α}]. In terms of testosterone-mediated genomic-dependent mechanisms of vasodilation, it has been hypothesised that testosterone upregulates the expression of endothelial nitric oxide synthase [eNOS], the enzyme responsible for synthesising nitric oxide [NO]. NO in turn brings about relaxation of SMCs and subsequent vasodilatation by activating guanylate cyclase which produces cGMP, which in turn activates cGMP-dependent protein kinase [PKG]. PKG phosphorylates and activates sarcoplasmic reticulum-ATPase [SERCA] which results in augmentation of calcium levels in the sarcoplasmic reticulum [38].

2.4.3. Vasoconstriction

Aside from its suggested role in vasodilation, there are a few basic studies that seem to implicate testosterone in vasoconstriction. A study carried out by Ammar *et al.* utilised male rabbits that were administered either 25mg/kg intramuscular testosterone weekly or no treatment, followed by the removal of the descending thoracic aorta. The vessel was then either contracted with 5-hydroxytryptamine [5-HT] or dilated with sodium nitroprusside [SNP]. This study showed that aortas from the testosterone-treated animals displayed a higher contractile percentage when exposed to 5-HT and a lower relaxation percentage when exposed to SNP, suggesting that testosterone limits vasodilatation and increases vasoconstriction. The aforementioned observations were statistically significant [44, 47].

A preliminary study conducted by Ammar *et al.* determined the effects of testosterone on isolated as well as perfused coronary arteries. The vasoconstrictive actions of testosterone were apparent [48]. It is believed that testosterone antagonises the vasodilatory effects of the vasodilator adenosine through increased vascular resistance and competes with other vasodilators, though a concrete mechanism has not been proposed [44, 48].

2.4.4. Cardioprotection

One study investigated the role of testosterone in organ reperfusion following vascular occlusion. Tsang *et al.* isolated rat hearts from control, orchietomised, and orchietomised plus testosterone treatment [2mg/kg daily for 8 weeks] groups. The coronary arteries were pre-occluded for 30 minutes and subsequently reperfused with a physiological solution for 120 minutes. Following isolation, it was observed that when compared to the control group, MI infarct size was largest in the orchietomised group, compared to the orchietomised plus testosterone treatment group. This finding suggests that testosterone may have a role in vascular reperfusion through which it can impart cardioprotection [44, 49].

2.4.5. Intima-Media Thickness

Intima media thickness [IMT] is a feature of atherosclerosis [50]. Demirbag *et al.* conducted a study in 42 male patients without a history of atherosclerosis, who were referred for transoesophageal echocardiography [TOE]. IMT was evaluated by TOE and testosterone levels quantified. The authors discovered an inverse relationship between total testosterone and intima media thickness in the abdominal aorta independent of cardiovascular disease. The results of the study therefore imply a preventative role of endogenous testosterone in coronary artery disease [51].

2.4.6. Gender Differences

The gender differences in testosterone physiology and plasma testosterone concentration in adolescent males and females cannot be ignored. According to Mayo Medical Laboratories, the SHBG-bound testosterone reference range in adolescent males and females at the pinnacle of pubertal development [Tanner stage V] suggests that there is a higher percentage of SHBG-bound testosterone in females [18-144nmol/L or 518-4149ng/dL] compared to males [10-57nmol/L or 288-1642ng/dL]. The physiological implication of this difference is yet to be unravelled. We propose a reservoir-like role for SHBG-bound testosterone to replenish circulating oestradiol in females *via* the actions of aromatase.

Some investigators believe that testosterone may be more harmful in females than in males [52 - 55]. This was echoed by an animal study that utilised rat aortic rings from either atherosclerotic tunica intima or healthy tunica media, as well as cultured rabbit SMCs. Female rat aortic rings treated with testosterone resulted in significant decreases in prostacyclin [PGI₂] synthesis whilst PGI₂ synthesis in male rat aortic rings remained unchanged. It was suggested that testosterone may induce atherogenic changes in females by modulating PGI₂ synthesis [56].

The beneficial effects of testosterone in males were also highlighted in another study where a group of testicular feminised mice [Tfm] and littermates were fed a cholesterol-rich diet for 28 weeks. They were then treated with exogenous testosterone alone, exogenous testosterone plus the oestrogen receptor α -antagonist fulvestrant, and exogenous testosterone plus the aromatase inhibitor anastrozole. It was found that exogenous testosterone replacement inhibited fatty streak formation in Tfm mice independent of the androgen receptor. Moreover, it was suggested that the observed HDL-C increment may have been attributed to the conversion of testosterone to 17 β -estradiol [57].

It is also important to consider how testosterone can potentiate the effects of CVD risk factors such as obesity in males. It was found that obese men had lower levels of total and free testosterone, as well as SHBG-bound testosterone, possibly due to upregulated aromatase activity which converts testosterone to oestradiol [58]. These individuals were concluded to be at a greater risk of developing CVD and impotency when compared to the control population [58]. Since the SHBG-bound testosterone levels were low, one may argue that increasing levels of SHBG-bound testosterone and concomitantly inhibiting aromatase may increase the circulating levels of free testosterone due to 'testosterone unloading', which may help to reduce the risk of impotency and CVD. Therefore, comparing testosterone physiology in males and females may help elucidate further mechanisms by which testosterone exerts its effects, as well as emphasizing the sex-specific pathophysiological mechanisms that implicate testosterone in CVD.

CONCLUSION

The scientific consensus from animal studies is vasodilatation, as studies supporting a role for vasoconstriction are limited and conflicting. The reported differences may be attributed to study design. The testosterone concentration utilised differed from study to study, as well as vascular exposure time to testosterone. It is logical to propose that depending on whether exposure to testosterone is acute or chronic, vasoconstriction or vasodilatation may be elicited to maintain vasomotor tone and haemodynamic homeostasis. It is also worth stating that the animal studies were carried out in different species and therefore species-dependent responses may have contributed to the observed differences. More importantly, the limitation of basic science studies is that the animal physiology is not always representative of human physiology, and may thus pose problems when research is translated from 'bench to bedside'.

The beneficial effects of testosterone in certain scenarios have meant that efforts have been made to explore possible avenues of increasing circulating testosterone concentrations. It was shown that endogenous insulin can help to increase testosterone synthesis and inhibit testosterone binding to SHBG, thereby decreasing concentrations of SHBG-bound testosterone and increasing free circulating testosterone [59]. Nevertheless, one has to consider the long-term effects of chronic insulin administration in non-diabetics as well as the issue of compliance, since insulin can only be administered intravenously due to risk of digestion. Furthermore, the study is limited due to a small study population size.

There are unanswered questions on whether or not men over the age of 50 with coronary artery disease should also be screened for hypogonadism. The difficulty lies in the fact that the role of hypotestosteronaemia in CVD whether causal or consequential, has not been established. If indeed a causal relationship exists then chronic low dose TRT may prove beneficial in clinical trials as this may improve cardiovascular outcome. It is also important to mention that no uniform definition exists for hypogonadism and thus different investigators define it differently in terms of the reference range. Introducing some standardization and consistency to androgen reference ranges that define hypogonadism and hypotestosteronaemia will help to shed light in terms of study design and targeting the right population for investigation and treatment [60 - 62].

All in all, there is emerging evidence to support the hypothesis that low testosterone levels predict a poor cardiovascular risk profile. Historically considered in the realms of reproductive biology and puberty, it is now clear that the roles of testosterone extend beyond that anticipated. Although we are still far from unmasking the roles and mechanisms of testosterone in the cardiac vasculature, one thing remains certain; that the future is bright. Testosterone holds great promise; possibly the hormone that will revolutionise the field of cardiovascular physiology.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

5-HT	=	5-hydroxytryptamine
5α-DHT	=	5 α -dihydrotestosterone
ACS	=	Acute Coronary Syndromes
ACTH	=	Adrenocorticotrophin hormone
AR	=	Androgen receptor
AS	=	Androstenedione
CAD	=	Coronary artery disease
cGMP	=	cyclic-Guanosine Monophosphate
CHD	=	Coronary heart disease
CVD	=	Cardiovascular disease
DHEA-S	=	Dehydroepiandrosterone sulphate
eNOS	=	Endothelial nitric oxide synthase
GIT	=	Gastrointestinal tract
GnRH	=	Gonadotrophin-releasing hormone
HDL-C	=	High density lipoprotein-cholesterol
HPA	=	Hypothalamic-pituitary-adrenal axis
HPG	=	Hypothalamic-pituitary-gonadal
IMT	=	Intima media thickness
KCs	=	Potassium Channels
KHB	=	Kreb-Henseleit Bicarbonate
LAD	=	Left anterior descending coronary arteries
LH	=	Luteinising hormone
L-NAME	=	N-nitro-L-arginine methyl ester
MI	=	Infarction
NHS	=	National Health Service
NO	=	Nitric oxide
NOS	=	Nitric oxide synthase
OxLDL	=	Oxidised Low Density Lipoprotein
PGF2α	=	Prostaglandin F2 α
RHD	=	Rheumatic heart disease
SERCA	=	Sacroplasmic reticulum-ATPase
SHBG	=	Sex Hormone Binding Globulin
SMCs	=	Smooth muscle cells
SNP	=	Sodium nitroprusside
SOCCs	=	Store-operated calcium channels
TOE	=	Transoesophageal echocardiography
TRT	=	Testosterone Replacement Therapy
VOCCs	=	Voltage-gated calcium channels
WHO	=	World Health Organisation

REFERENCES

- [1] World Health Organization (WHO). Global status report on noncommunicable diseases 2014. 2014; 1-302. Available at: <http://www.who.int/nmh/publications/ncd-status-report-2014/en/>
- [2] Celermajer DS, Ayer JG. Childhood risk factors for adult cardiovascular disease and primary prevention in childhood. *Heart* 2006; 92(11): 1701-6. [<http://dx.doi.org/10.1136/hrt.2005.081760>] [PMID: 17041125]
- [3] Fairweather D, Petri MA, Coronado MJ, Cooper LT. Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. *Expert Rev Clin Immunol* 2012; 8(3): 269-84. [<http://dx.doi.org/10.1586/eci.12.10>] [PMID: 22390491]
- [4] Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. *J Am Heart Assoc* 2013; 2(6): e000272. [<http://dx.doi.org/10.1161/JAHA.113.000272>] [PMID: 24242682]
- [5] Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc Res* 2008; 79(1): 14-23. [<http://dx.doi.org/10.1093/cvr/cvn099>] [PMID: 18430750]
- [6] Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. *Curr Opin Lipidol* 1998; 9(5): 471-4. [<http://dx.doi.org/10.1097/00041433-199810000-00012>] [PMID: 9812202]
- [7] Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. *Biochim Biophys Acta* 2000; 1488(3): 189-210. [[http://dx.doi.org/10.1016/S1388-1981\(00\)00123-2](http://dx.doi.org/10.1016/S1388-1981(00)00123-2)] [PMID: 11082530]
- [8] Samson S, Mundkur L, Kakkar VV. Immune response to lipoproteins in atherosclerosis. *Cholesterol* 2012; 2012: 571846 [<http://dx.doi.org/10.1155/2012/571846>]
- [9] Farb A, Burke AP, Tang AL, *et al.* Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. *Circulation* 1996; 93(7): 1354-63. [<http://dx.doi.org/10.1161/01.CIR.93.7.1354>] [PMID: 8641024]
- [10] Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. *Circulation* 1994; 90(2): 775-8. [<http://dx.doi.org/10.1161/01.CIR.90.2.775>] [PMID: 8044947]
- [11] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; 352(16): 1685-95. [<http://dx.doi.org/10.1056/NEJMra043430>] [PMID: 15843671]
- [12] Mendis S, Thygesen K, Kuulasmaa K, *et al.* World Health Organization definition of myocardial infarction: 2008-09 revision. *Int J Epidemiol* 2011; 40(1): 139-46. [<http://dx.doi.org/10.1093/ije/dyq165>] [PMID: 20926369]
- [13] Townsend N, Wickramasinghe K, Bhatnagar P, *et al.* Coronary heart disease statistics. London, England: British Heart Foundation 2012.
- [14] Hou JW, Collins DC, Schleicher RL. Sources of cholesterol for testosterone biosynthesis in murine Leydig cells. *Endocrinology* 1990; 127(5): 2047-55. [<http://dx.doi.org/10.1210/endo-127-5-2047>] [PMID: 2226298]
- [15] Zouboulis CC, Degitz K. Androgen action on human skin -- from basic research to clinical significance. *Exp Dermatol* 2004; 13(Suppl. 4): 5-10. [<http://dx.doi.org/10.1111/j.1600-0625.2004.00255.x>] [PMID: 15507105]
- [16] Xing Y, Edwards MA, Ahlem C, *et al.* The effects of ACTH on steroid metabolomic profiles in human adrenal cells. *J Endocrinol* 2011; 209(3): 327-35. [<http://dx.doi.org/10.1530/JOE-10-0493>] [PMID: 21429963]
- [17] Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med* 2013; 369(25): 2457. [PMID: 24350954]
- [18] Young JM, McNeilly AS. Theca: the forgotten cell of the ovarian follicle. *Reproduction* 2010; 140(4): 489-504. [<http://dx.doi.org/10.1530/REP-10-0094>] [PMID: 20628033]
- [19] Jin JM, Yang WX. Molecular regulation of hypothalamus-pituitary-gonads axis in males. *Gene* 2014; 551(1): 15-25. [<http://dx.doi.org/10.1016/j.gene.2014.08.048>] [PMID: 25168889]
- [20] Keenan DM, Veldhuis JD. Divergent gonadotropin-gonadal dose-responsive coupling in healthy young and aging men. *Am J Physiol Regul Integr Comp Physiol* 2004; 286(2): R381-9. [<http://dx.doi.org/10.1152/ajpregu.00376.2003>] [PMID: 14592930]
- [21] Veldhuis JD, Keenan DM, Liu PY, Iranmanesh A, Takahashi PY, Nehra AX. The aging male hypothalamic-pituitary-gonadal axis: pulsatility and feedback. *Mol Cell Endocrinol* 2009; 299(1): 14-22. [<http://dx.doi.org/10.1016/j.mce.2008.09.005>] [PMID: 18838102]

- [22] Pasquali R. The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects. *Ann N Y Acad Sci* 2012; 1264: 20-35. [http://dx.doi.org/10.1111/j.1749-6632.2012.06569.x] [PMID: 22612409]
- [23] Matsumoto T, Sakari M, Okada M, *et al.* The androgen receptor in health and disease. *Annu Rev Physiol* 2013; 75: 201-24. [http://dx.doi.org/10.1146/annurev-physiol-030212-183656] [PMID: 23157556]
- [24] Bain J. Testosterone and the aging male: to treat or not to treat? *Maturitas* 2010; 66(1): 16-22. [http://dx.doi.org/10.1016/j.maturitas.2010.01.009] [PMID: 20153946]
- [25] Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. *J Clin Endocrinol Metab* 2006; 91(8): 3024-33. [http://dx.doi.org/10.1210/jc.2006-0357] [PMID: 16705073]
- [26] Tivesten A, Movérare-Skrtic S, Chagin A, *et al.* Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. *J Bone Miner Res* 2004; 19(11): 1833-9. [http://dx.doi.org/10.1359/JBMR.040819] [PMID: 15476584]
- [27] Davey RA, Morris HA. Effects of estradiol and dihydrotestosterone on osteoblast gene expression in osteopenic ovariectomized rats. *J Bone Miner Metab* 2005; 23(3): 212-8. [http://dx.doi.org/10.1007/s00774-004-0586-z] [PMID: 15838623]
- [28] Ferrucci L, Maggio M, Bandinelli S, *et al.* Low testosterone levels and the risk of anemia in older men and women. *Arch Intern Med* 2006; 166(13): 1380-8. [http://dx.doi.org/10.1001/archinte.166.13.1380] [PMID: 16832003]
- [29] Calof OM, Singh AB, Lee ML, *et al.* Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. *J Gerontol A Biol Sci Med Sci* 2005; 60(11): 1451-7. [http://dx.doi.org/10.1093/gerona/60.11.1451] [PMID: 16339333]
- [30] Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. *Am J Psychiatry* 2003; 160(1): 105-11. [http://dx.doi.org/10.1176/appi.ajp.160.1.105] [PMID: 12505808]
- [31] Azad N, Pitale S, Barnes WE, Friedman N. Testosterone treatment enhances regional brain perfusion in hypogonadal men. *J Clin Endocrinol Metab* 2003; 88(7): 3064-8. [http://dx.doi.org/10.1210/jc.2002-020632] [PMID: 12843144]
- [32] Bhasin S, Cunningham GR, Hayes FJ, *et al.* Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010; 95(6): 2536-59. [http://dx.doi.org/10.1210/jc.2009-2354] [PMID: 20525905]
- [33] Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. *Am J Med* 2011; 124(7): 578-87. [http://dx.doi.org/10.1016/j.amjmed.2010.12.027] [PMID: 21683825]
- [34] Haring R, Völzke H, Steveling A, *et al.* Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. *Eur Heart J* 2010; 31(12): 1494-501. [http://dx.doi.org/10.1093/eurheartj/ehq009] [PMID: 20164245]
- [35] Khaw KT, Dowsett M, Folkler E, *et al.* Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation* 2007; 116(23): 2694-701. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.719005] [PMID: 18040028]
- [36] Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. *Circulation* 2005; 112(3): 332-40. [http://dx.doi.org/10.1161/CIRCULATIONAHA.104.489088] [PMID: 16009799]
- [37] Araujo AB, O'Donnell AB, Brambilla DJ, *et al.* Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2004; 89(12): 5920-6. [http://dx.doi.org/10.1210/jc.2003-031719] [PMID: 15579737]
- [38] Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. *J Endocrinol* 2013; 217(3): R47-71. [http://dx.doi.org/10.1530/JOE-12-0582] [PMID: 23549841]
- [39] Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? *Trends Endocrinol Metab* 2010; 21(8): 496-503. [http://dx.doi.org/10.1016/j.tem.2010.03.002] [PMID: 20381374]
- [40] Arnlöv J, Pencina MJ, Amin S, *et al.* Endogenous sex hormones and cardiovascular disease incidence in men. *Ann Intern Med* 2006; 145(3): 176-84. [http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00005] [PMID: 16880459]
- [41] English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. *Circulation* 2000; 102(16): 1906-11. [http://dx.doi.org/10.1161/01.CIR.102.16.1906] [PMID: 11034937]

- [42] Rosano GM, Leonardo F, Pagnotta P, *et al.* Acute anti-ischemic effect of testosterone in men with coronary artery disease. *Circulation* 1999; 99(13): 1666-70.
[<http://dx.doi.org/10.1161/01.CIR.99.13.1666>] [PMID: 10190874]
- [43] Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease 1999; 83(3): 437-439, A9.
[[http://dx.doi.org/10.1016/S0002-9149\(98\)00880-7](http://dx.doi.org/10.1016/S0002-9149(98)00880-7)]
- [44] Herring MJ, Oskui PM, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. *J Am Heart Assoc* 2013; 2(4): e000271.
[<http://dx.doi.org/10.1161/JAHA.113.000271>] [PMID: 23842280]
- [45] Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. *Am J Physiol Heart Circ Physiol* 2001; 281(4): H1720-7.
[PMID: 11557563]
- [46] Jones RD, English KM, Jones TH, Channer KS. Testosterone-induced coronary vasodilatation occurs *via* a non-genomic mechanism: evidence of a direct calcium antagonism action. *Clin Sci* 2004; 107(2): 149-58.
[<http://dx.doi.org/10.1042/CS20030386>] [PMID: 14992681]
- [47] Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. *Pharmacol Res* 2004; 50(3): 253-9.
[<http://dx.doi.org/10.1016/j.phrs.2004.03.010>] [PMID: 15225667]
- [48] Ceballos G, Figueroa L, Rubio I, *et al.* Acute and nongenomic effects of testosterone on isolated and perfused rat heart. *J Cardiovasc Pharmacol* 1999; 33(5): 691-7.
[<http://dx.doi.org/10.1097/00005344-199905000-00003>] [PMID: 10226854]
- [49] Tsang S, Wu S, Liu J, Wong TM. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of $\alpha(1)$ -adrenoceptor stimulation. *Br J Pharmacol* 2008; 153(4): 693-709.
[<http://dx.doi.org/10.1038/sj.bjp.0707624>] [PMID: 18157169]
- [50] Crouse JR III, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. *Circulation* 1995; 92(5): 1141-7.
[<http://dx.doi.org/10.1161/01.CIR.92.5.1141>] [PMID: 7648658]
- [51] Demirbag R, Yilmaz R, Ulucay A, Unlu D. The inverse relationship between thoracic aortic intima media thickness and testosterone level. *Endocr Res* 2005; 31(4): 335-44.
[<http://dx.doi.org/10.1080/07435800500449494>] [PMID: 16433252]
- [52] Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. *Metabolism* 2008; 57(7): 961-5.
[<http://dx.doi.org/10.1016/j.metabol.2008.02.012>] [PMID: 18555838]
- [53] Patel SM, Ratcliffe SJ, Reilly MP, *et al.* Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. *J Clin Endocrinol Metab* 2009; 94(12): 4776-84.
[<http://dx.doi.org/10.1210/jc.2009-0740>] [PMID: 19846742]
- [54] Rohr UD. The impact of testosterone imbalance on depression and women's health. *Maturitas* 2002; 41(Suppl. 1): S25-46.
[[http://dx.doi.org/10.1016/S0378-5122\(02\)00013-0](http://dx.doi.org/10.1016/S0378-5122(02)00013-0)] [PMID: 11955793]
- [55] Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. Androgen in postmenopausal women. *J Med Invest* 2012; 59(1-2): 12-27.
[<http://dx.doi.org/10.2152/jmi.59.12>] [PMID: 22449989]
- [56] Wakasugi M, Noguchi T, Kazama YI, Kanemaru Y, Onaya T. The effects of sex hormones on the synthesis of prostacyclin (PGI₂) by vascular tissues. *Prostaglandins* 1989; 37(4): 401-10.
[[http://dx.doi.org/10.1016/0090-6980\(89\)90090-7](http://dx.doi.org/10.1016/0090-6980(89)90090-7)] [PMID: 2669031]
- [57] Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. *Circulation* 2007; 116(21): 2427-34.
[<http://dx.doi.org/10.1161/CIRCULATIONAHA.107.708768>] [PMID: 17984376]
- [58] Wang C, Jackson G, Jones TH, *et al.* Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. *Diabetes Care* 2011; 34(7): 1669-75.
[<http://dx.doi.org/10.2337/dc10-2339>] [PMID: 21709300]
- [59] Pasquali R, Casimirri F, De Iasio R, *et al.* Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. *J Clin Endocrinol Metab* 1995; 80(2): 654-8.
[PMID: 7852532]
- [60] Schrör K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV. Testosterone treatment enhances thromboxane A₂ mimetic induced coronary artery vasoconstriction in guinea pigs. *Eur J Clin Invest* 1994; 24(Suppl. 1): 50-2.
[<http://dx.doi.org/10.1111/j.1365-2362.1994.tb02428.x>] [PMID: 8013532]
- [61] Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. *Am J Ther* 1999; 6(3): 167-74.

[<http://dx.doi.org/10.1097/00045391-199905000-00008>] [PMID: 10423660]

- [62] Vigen R, O'Donnell CI, Barón AE, *et al.* Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA* 2013; 310(17): 1829-36.

[<http://dx.doi.org/10.1001/jama.2013.280386>] [PMID: 24193080]

Received: August 22, 2015

Revised: September 20, 2015

Accepted: October 22, 2015

© Tambo *et al.*; Licensee *Bentham Open*.

This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (<https://creativecommons.org/licenses/by-nc/4.0/legalcode>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.